#ai-tools

Leaked internal messages reveal Sam Altman strategized in 2023 to release a local GPT-3-class model to suppress competitors and dry up funding; separately, a security researcher found a WordPress RCE using GPT-5.6 for $25, and Kimi K3's 2.8T open-weights release continued pressure on closed frontier labs. In pharma, Eli Lilly's psychedelics acquisition drew further industry analysis, GSK axed its key cough drug candidate, and a state Medicaid audit exposed PBM cost-obscuring tactics. The economy section covers Waymo safety data, the UK as a cautionary macro tale, and Basel III's hidden fragility inside bank holding companies.

OpenAI quietly launched GPT-5.6 in three tiers (Sol, Terra, Luna) restricted to trusted partners, while Semgrep reported that GLM 5.2 outperforms Claude on its internal cybersecurity benchmarks. Portugal's National Health Service contracted Sword Health to deliver AI-assisted physical therapy nationwide, the first country-scale deployment of its kind. Edison Scientific and Population Health Partners announced a deal to use AI agents for end-to-end drug discovery. Patrick Boyle assessed Brexit's 10-year economic toll, and Noah Smith examined whether AI will push companies toward more or less outsourcing.

Microsoft unveiled two proprietary MAI models at Build, including a 1-trillion-parameter reasoning model and a 137B coding model for GitHub Copilot, as Uber hit its AI budget ceiling after burning through its full 2026 allocation in four months. Alnylam struck a $2 billion deal with Inceptive Nucleics to build AI foundation models for RNA interference therapeutics. Trump signed a narrower AI oversight executive order requiring a 30-day review before powerful open-weight models can be released. The Trump administration also moved to strip job protections from roughly 8,000 NIH staff, including officials who oversee research grants, while Medicaid work requirements drew criticism for going beyond what advocates had anticipated.